To quantify the changes in CT26 tumor-infiltrating lymphocytes (TILs) in response to therapy, we analyzed the distribution of different immune cell subsets of TRs to different therapeutic strategies and compared this to the TNR group (Fig. 4). This evidence concerns the gene TNR and neoplasm.